Mirae Asset Global Investments Co. Ltd. Buys New Shares in Perrigo Company plc (NYSE:PRGO)

Mirae Asset Global Investments Co. Ltd. bought a new position in Perrigo Company plc (NYSE:PRGO - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 28,813 shares of the company's stock, valued at approximately $927,000.

Other institutional investors have also recently bought and sold shares of the company. London Co. of Virginia increased its holdings in shares of Perrigo by 1.1% during the 3rd quarter. London Co. of Virginia now owns 2,818,468 shares of the company's stock worth $90,050,000 after purchasing an additional 30,239 shares during the period. Cooper Creek Partners Management LLC increased its holdings in shares of Perrigo by 1,080.0% during the 3rd quarter. Cooper Creek Partners Management LLC now owns 1,872,508 shares of the company's stock worth $59,827,000 after purchasing an additional 1,713,827 shares during the period. Northern Trust Corp increased its holdings in shares of Perrigo by 0.3% during the 3rd quarter. Northern Trust Corp now owns 1,582,731 shares of the company's stock worth $50,568,000 after purchasing an additional 4,373 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in shares of Perrigo by 5.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,379,041 shares of the company's stock worth $44,060,000 after purchasing an additional 65,123 shares during the period. Finally, Heartland Advisors Inc. increased its holdings in shares of Perrigo by 17.2% during the 3rd quarter. Heartland Advisors Inc. now owns 1,124,596 shares of the company's stock worth $35,931,000 after purchasing an additional 164,849 shares during the period. Institutional investors own 95.91% of the company's stock.

Insider Buying and Selling at Perrigo

In other news, EVP Alison Ives purchased 2,490 shares of Perrigo stock in a transaction on Tuesday, March 5th. The shares were purchased at an average cost of $27.26 per share, for a total transaction of $67,877.40. Following the completion of the transaction, the executive vice president now directly owns 16,122 shares in the company, valued at $439,485.72. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, EVP Alison Ives bought 2,490 shares of the company's stock in a transaction on Tuesday, March 5th. The stock was bought at an average cost of $27.26 per share, with a total value of $67,877.40. Following the completion of the purchase, the executive vice president now owns 16,122 shares in the company, valued at approximately $439,485.72. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Patrick Lockwood-Taylor bought 9,500 shares of the company's stock in a transaction on Thursday, February 29th. The stock was bought at an average cost of $26.54 per share, with a total value of $252,130.00. Following the completion of the purchase, the chief executive officer now owns 20,500 shares of the company's stock, valued at approximately $544,070. The disclosure for this purchase can be found here. Insiders have bought a total of 17,990 shares of company stock worth $475,227 over the last ninety days. Corporate insiders own 0.40% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on PRGO. Piper Sandler boosted their price objective on shares of Perrigo from $35.00 to $39.00 and gave the stock an "overweight" rating in a report on Monday, April 8th. Canaccord Genuity Group reiterated a "buy" rating and set a $42.00 target price on shares of Perrigo in a research report on Friday, April 12th. JPMorgan Chase & Co. decreased their target price on shares of Perrigo from $48.00 to $41.00 and set an "overweight" rating on the stock in a research report on Wednesday, February 28th. Finally, StockNews.com upgraded shares of Perrigo from a "hold" rating to a "buy" rating in a research report on Wednesday, April 3rd.

Perrigo Price Performance

Shares of Perrigo stock traded up $0.74 during trading on Wednesday, hitting $31.23. 963,646 shares of the company's stock traded hands, compared to its average volume of 1,833,058. The company has a market cap of $4.23 billion, a PE ratio of -312.30 and a beta of 0.64. Perrigo Company plc has a twelve month low of $25.77 and a twelve month high of $40.28. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.79 and a quick ratio of 1.07. The firm's fifty day moving average price is $30.54 and its 200 day moving average price is $30.78.

Perrigo (NYSE:PRGO - Get Free Report) last released its quarterly earnings results on Tuesday, February 27th. The company reported $0.86 EPS for the quarter, beating analysts' consensus estimates of $0.83 by $0.03. The firm had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.17 billion. Perrigo had a negative net margin of 0.27% and a positive return on equity of 7.34%. The company's revenue for the quarter was up .1% compared to the same quarter last year. During the same period in the previous year, the business earned $0.75 earnings per share. Analysts forecast that Perrigo Company plc will post 2.55 earnings per share for the current year.

Perrigo Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, March 26th. Shareholders of record on Friday, March 8th were given a $0.276 dividend. The ex-dividend date was Thursday, March 7th. This is a positive change from Perrigo's previous quarterly dividend of $0.27. This represents a $1.10 dividend on an annualized basis and a yield of 3.54%. Perrigo's payout ratio is -1,100.00%.

About Perrigo

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.